Early data from AC Immune Alzheimer's vaccine suggests a response, setting up next phase of study

It’s early days for AC Immune’s Alzheimer’s disease vaccine, but a sneak peek at phase 1b/2 data showed the anti-amyloid beta vaccine elicited a response, allowing it to move up to a higher dose in the trial.